A 45-member modified Delphi consensus: screen for eating disorders before GLP-1 receptor agonist prescribing, and generally avoid these agents in active anorexia and bulimia nervosa
Using a three-round modified Delphi method, a 45-member panel of clinicians and researchers in diabetes, obesity and/or eating disorders plus people with lived experience reached an average 91.7% consensus on recommendations for GLP-1 receptor agonist use in eating disorder contexts, covering pre-treatment screening, risk-stratified monitoring, standardized educational materials and concurrent evidence-based psychotherapy, stating that these agents should generally be avoided in active eating disorders, particularly anorexia nervosa, atypical anorexia nervosa and bulimia nervosa with marked dietary restraint and/or significant weight suppression, and setting out research priorities in epidemiology, regulation and binge eating disorder trials.